JAK / TYK2
7 articles
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Generative AI Designs Spirocyclic Dual Degraders Bridging Innate and Adaptive Immunity Kinases
- A VAE-RNN generative model in the POLYGON framework explored chemical space between two unrelated kinase families, IRAK4 and TYK2.
- Iterative sampling, scoring and refocusing cycles avoided the limits of simple pharmacophore merging and produced a structurally novel spirocyclic scaffold.
- Water-site analysis with WaterMap guided optimization, and PROTAC conjugation then gave a dual degrader, C-8-014.
- The compound efficiently degrades both kinases, supporting a closed-loop AI design approach for hard-to-reach kinome regions.
Spirocyclic cores are attractive for 3D character and IP space, but a dual IRAK4/TYK2 binder is only half the story here. The ATP pockets share little beyond the hinge, so I'd want biochemical affinity and kinome selectivity for the parent warhead before PROTAC conjugation, plus a non-degrading control. Degradation can also hide weak binding, so ternary complex and E3 dependence need checking, and so does synthetic tractability of the spirocycle.
PharmacologyBiochemical Pharmacology
Knocking Down Hepatic GPR146 Shrinks Plaques in ApoE-Deficient Mice
- Hepatic AAV-mediated GPR146 knockdown was tested in high-fat-fed ApoE-deficient mice, with rosuvastatin as a comparator arm.
- Knockdown reduced plaque burden, circulating cholesterol and plaque inflammation; GPR146 was also up-regulated in macrophage-rich lesion regions.
- In ox-LDL-treated macrophages, silencing GPR146 lowered CD36 and foam-cell formation and dampened pro-inflammatory activation, with JAK-STAT implicated.
The liver-lipid and macrophage-inflammation claims are mixed in one story, but hepatic knockdown cannot tell you which one cleared the plaque; a macrophage-specific knockout would. GPR146 is an orphan GPCR with no validated agonist or antagonist, so the next hard question is ligandability, and whether any compound could match a statin on top-line efficacy rather than just add to it.
Computational & AIDigital Discovery (RSC)
AI-guided design, robotic synthesis and automated screening are linked into a closed loop that yields improved JAK-family inhibitors over two cycles
- Combines generative molecular design guided by an affinity predictor, AI retrosynthesis, robotic synthesis and automated screening, with expert oversight for some synthesis and purification steps.
- Applied to four JAK-family targets (JAK1, JAK2, JAK3, TYK2) over two design-make-test-analyse cycles, with a few dozen compounds made or purchased and tested experimentally.
- The first round mainly produced analogs of known inhibitors; the second round gave compounds with improved potency and ligand efficiency across all four targets.
Round one returning analogs of known inhibitors suggests the generator mostly leaned on JAK chemotypes already in the training data, so improved potency in round two may reflect optimizing a familiar scaffold. Without a matched manual or random-selection arm, the loop's added value is unclear. Ask for selectivity data across the JAK paralogs, since potency alone is easy to gain.
PharmacologyBritish Journal of Pharmacology (Wiley)
Review: measuring covalent inhibitor kinetics and linking them to in vivo effect
- Lead selection leans on equilibrium IC50 values, which ignore how drug and target levels shift over time; this matters most for irreversible covalent drugs.
- The review surveys assays for kinact and KI: progress curves, multi-timepoint IC50 fitting for library triage, mass spectrometry for adducts and sites, SPR/NMR, and washout experiments for reversibility and residence time.
- It then links these rates to pharmacology via protein turnover, target vulnerability and pharmacokinetics, using BTK, JAK3, KRAS G12C and EGFR cases.
On a covalent hit, an IC50 from a single timepoint says little, because potency drifts with incubation time and ranking by it can bury the compound with the best kinact/KI. Translation is the harder part: in vivo occupancy depends on how fast the target is resynthesized, so a fast-turnover protein can blunt even a well-optimized warhead. Measure turnover before trusting the kinetics.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Review maps covalent kinase inhibitors across EGFR, BTK, FGFR and JAK3
- This is a review article, not a primary study, covering 35 approved and investigational covalent kinase inhibitors.
- It focuses on four families that target a non-catalytic cysteine near the ATP pocket: EGFR (Cys797), BTK (Cys481), FGFR (Cys488) and JAK3 (Cys909).
- Each inhibitor is discussed for discovery history, binding mode, SAR, indications and synthesis, along with off-target toxicity and acquired resistance such as EGFR C797S.
Four cysteines, four very different risk profiles. Cys481 in BTK and Cys797 in EGFR are well-validated handles, but the C797S escape mutation shows the weakness: lose the nucleophile and the whole warhead strategy collapses, so reversible or allosteric backups matter. JAK3's Cys909 is the interesting one, since it can buy isoform selectivity that ATP-site binders struggle with, though acrylamide reactivity across the kinome remains the tox question.
Industry NewsMaruho / Bristol Myers SquibbAnswersNews
Maruho and BMS Partner on Japan Sales for TYK2 Inhibitor Sotyktu
- Maruho and Bristol Myers Squibb (BMS) signed a Japan sales partnership for Sotyktu (deucravacitinib), BMS's oral TYK2 inhibitor, starting October 1, 2026.
- Maruho will handle domestic sales and distribution, promoting the drug in dermatology and rheumatology, while BMS continues promotion in rheumatology.
- Sotyktu is approved for plaque, pustular and erythrodermic psoriasis, with a psoriatic arthritis indication added in May 2026.
BMS ceding Japan commercial lead to Maruho is a tacit admission that dermatologist relationships beat global scale here — the classic foreign-innovator/domestic-specialist access play. Adding rheumatology promotion right after the May PsA nod signals urgency to outrun oral JAK rivals before positioning hardens. For Maruho, it's low-risk topline padding that fits its derm book without R&D exposure.
Industry NewsAlumisEndpoints News
Alumis' Lupus Trial Misses Goals Overall, but High-Interferon Subgroup Responds
- Alumis' Phase 2b LUMUS trial of envudeucitinib, an oral TYK2 inhibitor, missed its primary and key secondary endpoints in the overall lupus (SLE) patient population.
- A prespecified subgroup with a high interferon gene signature (IFNGS-high) — the patient profile most reliant on the Type I interferon pathway that TYK2 inhibition targets — showed a clear, placebo-separated response on the same endpoints.
- These IFNGS-high patients were underrepresented in the overall study population, which diluted the topline result.
- The drug was well tolerated, with no new safety signals.
- Alumis plans to redesign its Phase 3 program around IFNGS-high patients, engage the FDA before year-end, and separately still intends to file for U.S. psoriasis approval by the end of 2026.
A miss with an asterisk, not a pivot. IFNGS-high response is biologically coherent — interferon signature is literally TYK2's mechanism — so this isn't pure spin like some post-hoc subgroup rescues. But shrinking Phase 3 to biomarker-enriched patients trades a bigger addressable market for a better shot at significance; that's the right call scientifically, wrong one commercially unless a companion diagnostic scales cleanly. Versus BMS's already-approved Sotyktu, Alumis needed a clean topline to differentiate TYK2 in autoimmune beyond psoriasis — it didn't get one. Expect the Street to stay skeptical until FDA blesses the enrichment strategy; a >50% drop doesn't reverse on a CEO's confidence alone. Psoriasis filing is now doing the heavy lifting for the story — good, since it's biomarker-agnostic — but lupus was supposed to be the platform proof point, and that thesis just got smaller.